On February 19, 2025, CSPC Megalith reached an agreement with Radiance Biopharma, Inc. (hereinafter referred to as "Radiance Biopharma"). Under the terms of the agreement, Radiance Biopharma will obtain the exclusive rights to develop and commercialize the SYS6005 project (hereinafter referred to as "the Product"), which was independently developed by CSPC Megalith and is protected by independent intellectual property rights, in the United States, the EU, the UK, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada (hereinafter referred to as "the Licensed Territory"). Subsequently, Radiance Biopharma will also gain the exclusive rights to manufacture the Product in accordance with the clinical/commercial supply agreement.

On December 18, 2023, a Cooperation Framework Agreement on the Research and Development of Dengue Vaccines and Related Matters was jointly signed with CSPC International. The agreement will focus on the research and development of dengue mRNA vaccines, fully utilizing and leveraging the respective advantages of both parties in technology and resources. It aims to participate in and promote the cooperation between CSPC International and the Agency for Science, Technology and Research in Singapore in the development of dengue mRNA vaccines, and to complete related early research, clinical trials, and drug registration of the collaborative products in Singapore, Southeast Asia, and even major tropical disease regions worldwide, to achieve global sales and promotion of the product.

On July 28, 2023, CSPC Megalith entered into an exclusive licensing agreement with Elevation Oncology for the development and commercialization of the Group's innovative (first-in-class) anti-Claudin 18.2 antibody-drug conjugate SYSA1801 outside the Greater China region (including Mainland China, Hong Kong, Macau, and Taiwan).

On February 13, 2023, CSPC Megalith entered into an exclusive licensing agreement with Corbus Pharmaceuticals for the development and commercialization of the Group's humanized anti-Nectin-4 antibody-drug conjugate SYS6002 in the United States, EU countries, the United Kingdom, Canada, Australia, Iceland, Liechtenstein, Norway, and Switzerland.